Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. 1988

G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p less than 0.05). Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699

Related Publications

G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
June 1984, Cancer,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
September 1987, Lancet (London, England),
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
December 1984, Cancer treatment reviews,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
March 1992, The Journal of steroid biochemistry and molecular biology,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
October 1984, Thrombosis and haemostasis,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
February 1996, Thrombosis and haemostasis,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
January 1986, The Australian and New Zealand journal of surgery,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
January 1983, Clinical and experimental hypertension. Part B, Hypertension in pregnancy,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
February 1994, Cancer,
G Bertelli, and P Pronzato, and D Amoroso, and M P Cusimano, and P F Conte, and G Montagna, and S Bertolini, and R Rosso
August 1987, Cancer research,
Copied contents to your clipboard!